EGFR and cancer: The N-glycosylation difference at this site between these paired HCT116 cancer cells and DKO1 non-tumorigenic cells suggests the N-glycosylation at N175 may be used as a cancer biomarker or may contribute to EGFR as an oncogenic driver.